Shift to high‐intensity, low‐volume perfusion cell culture enabling a continuous, integrated bioprocess
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In order to address the increasing demand for biologics, cell culture intensification using perfusion offers significantly higher productivities while also reducing manufacturing costs, especially when part of an integrated, continuous bioprocess. An initial study of a long‐duration perfusion process using a cell‐bleed to maintain a target cell density observed a 2.1‐fold higher cell‐specific productivity and a gradual decline in the culture growth rate when perfused at an overall lower rate. Subsequent studies sought an alternative process that largely reduced the overall volume of media needed by first perfusing at a high cell‐specific perfusion rate (CSPR) to support a high cell density followed by continued perfusion at a low CSPR to promote a more productive stationary phase. This high intensity, low‐volume perfusion (HILVOP) process achieved cumulative volumetric productivities of 1.5–1.6 g/L/day with two CHO cell lines. When compared to each cell line's respective commercial‐ready, fed‐batch process, a 3.1–3.8‐fold productivity increase was demonstrated while yielding similar product quality. Furthermore, the higher productivity achieved with HILVOP used 6.6–12.3‐fold less media than a similarly productive long‐duration process . © 2018 American Institute of Chemical Engineers Biotechnol. Prog ., 34:1472–1481, 2018
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · cited 1×
“Productivity increases over the past three decades have been significant with fed-batch titers now reaching 5–10 g/L.(1,2) Despite better control of classic metabolic byproducts such as lactate, ammonium, and dissolved carbon dioxide, accumulation of other byproducts still eventually limit cell division and per-cell p…”
BackgroundDu, Z., Treiber, D., McCarter, J. D., Fomina‐Yadlin, D., Saleem, R. A., McCoy, R. E., Zhang, Y., Tharmalingam, T., Leith, M., Follstad, B. D., et al. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25332 · Cited by 113
Cited by
Perfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., et al. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1998821 · Cited by 55
Yilmaz, D., Mehdizadeh, H., Navarro, D., Shehzad, A., O'Connor, M., & McCormick, P. (2020) · Biotechnology Progress · doi:10.1002/btpr.2947 · Cited by 51
Hydrocyclones as cell retention device for CHO perfusion processes in single-use bioreactors
Bettinardi, I. W., Castan, A., Medronho, R. A., & Castilho, L. R. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27335 · Cited by 29
“The low specific growth rate observed in later stages of runs #2 and #3 (Figures 5f and 6f), which is a common feature of perfusion processes (Clincke et al., 2013; Gagnon et al., 2018; Wang et al., 2017), might be related to the increase in more fully glycosylated species over time.”
BackgroundLucas, C., Blackman, M., Rayat, A., Mainwaring, D., & Micheletti, M. (2024) · Journal of Advanced Manufacturing and Processing · doi:10.1002/amp2.10180 · Cited by 4
Metadata
- Authors
- Gagnon, M., Nagre, S., Wang, W., & Hiller, G. W.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2018-10-31
- Volume
- 34
- Issue
- 6
- Pages
- 1472-1481
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W2897121698
- Cited by
- 46
- References
- 2
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.